Insider trading activity within Aditxt Inc. (NASDAQ: ADTX) has drawn attention following a Form 4 filing submitted to the Securities and Exchange Commission on June 11, 2026. The filing details transactions executed by HRT Financial LP, a significant shareholder holding a 10% ownership stake in the company, between June 8 and June 10, 2026. This period of trading activity coincides with a severe downturn in the stock's market performance, where ADTX shares have fallen by 76% over a single week, currently hovering near $0.01, a level close to its 52-week low of $0.02. According to data from InvestingPro, the company's market capitalization has contracted to a mere $10,000.
HRT Financial LP engaged in simultaneous buying and selling operations. On the acquisition side, the firm purchased a total of 2,148,823 shares across two distinct transactions, with a combined value of $83,532. The purchase prices varied, ranging from $0.019 to $0.049 per share. Specifically, on June 8, 2026, HRT Financial LP acquired 1,423,493 shares at a price of $0.049 per share. Two days later, on June 10, 2026, the firm completed an additional purchase of 725,330 shares at a lower price point of $0.019 per share.
Conversely, the filing indicates that HRT Financial LP also divested a portion of its holdings. On June 9, 2026, the firm sold 878,659 shares of Aditxt common stock at a price of $0.033 per share, generating a total of $28,995. Following these reported transactions, HRT Financial LP's direct ownership stands at 1,040,004 shares of Aditxt common stock.
The trading activity unfolds against a backdrop of significant corporate restructuring and financial maneuvering by Aditxt. The company recently announced that its subsidiary, Ignite Proteomics LLC, will become an independent publicly traded entity through a special purpose acquisition company (SPAC) transaction. This deal values Ignite at an implied equity value of approximately $150 million. To oversee this transition, Aditxt has appointed Jeffrey M. Busch as interim CEO, a role in which he will continue to serve while remaining CEO of Ignite Proteomics.
Further complicating the company's recent history, Aditxt implemented a 1-for-27 reverse stock split, effective May 18, 2026, following stockholder approval at the annual meeting. In terms of capital structure, the company disclosed a $1.25 million private placement of senior unsecured notes. These notes carry an annual interest rate of 10% and are set to mature on September 30, 2026. Additionally, Aditxt reported regaining compliance with Nasdaq listing standards, a status confirmed by a letter from The Nasdaq Stock Market LLC. This compliance was predicated on the company's annual report, which showed stockholders' equity of $3,953,682.
InvestingPro Tips highlight critical financial health indicators for ADTX, noting that the company is rapidly depleting cash reserves and carries a substantial debt burden. These factors contribute to an overall "WEAK" rating for the company's financial health. The combination of insider trading activity, sharp stock declines, and complex corporate restructuring presents a multifaceted view of Aditxt's current operational and financial landscape.